Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis.

Authors :: Neumann B
Foerster S
Zhao C
Bodini B
Reich DS
Bergles DE
Káradóttir RT
Lubetzki C
Lairson LL
Zalc B
Stankoff B
Franklin RJM
Source :: Cell stem cell [Cell Stem Cell] 2020 May 07; Vol. 26 (5), pp. 617-619.
Publication Year :: 2020
Abstract: Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS.<br />Competing Interests: Declarations of Interest R.J.M.F. is a scientific advisory board member of Frequency Therapeutics, Rewind Therapeutics, and Biogen and has received research funding from Biogen. D.S.R. has received research funding from Vertex Pharmaceuticals. C.L. is an advisory board member of Merck-Serono, Roche, Rewind Therapeutics, and Biogen.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)